

## **REMARKS**

### **Allowable Subject Matter**

Applicants gratefully acknowledge the Examiner's indication that claims 1-3, 6-31 and 33-5a8 re free of the prior art.

### **Amendments**

Claim 31 is amended to be directed to thromboembolic diseases. See, e.g., page 4, lines 1-5 of the specification. In addition, claims 27, 28, 52, 53, and 57. These amendments clearly place the application in better condition for allowance, and undeniably reduce the number of issues for appeal. Entry of the amendments is respectfully requested.

### **Withdrawn Subject Matter and Claim Objections**

With respect to the Restriction Requirement and the objection to presence of non-elected subject matter in claims 1-3, 6-31, and 33-58, applicants filed a Petition on September 28, 2006.

### **Rejection under 35 USC § 112, first paragraph, enablement**

Claims 27, 28, 31, 33, 52, 53, and 57 are rejected under 35 USC § 112, first paragraph, on grounds of alleged lack of enablement. This rejection is respectfully traversed.

By the above amendments, claims 27, 28, 52, 53, and 57 are cancelled. Further, claim 31 is amended to be directed to thromboembolic diseases. Claim 33 depends from claim 31. These amendments are submitted for purposes of furthering prosecution and do not constitute acquiescence to any ground of rejection.


The Examiner has acknowledges that the claims are enabling for the treatment of thromboembolic disorders. See the paragraph bridging pages 5-6 of the Office Action. Thus, the amendments to the claims obviate the rejection. Withdrawal of the rejection under 35 USC § 112, first paragraph, is respectfully requested.

In the rejection, it is asserted that the claims are not enabling for the treatment of tumors or inflammation. Applicants maintain that the rejection does not present sufficient

reasons to doubt the veracity of the enablement statements in the specification, especially since one of ordinary skill in the art is well aware of the use of inhibitors of factor VIIa, factor IXa, and thrombin in the treatment of such diseases. See references cited in applicants' specification as well as, for example, US 5,798,332, US 6,500,803, US 6,794,507, and US 6,946,489.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Brion P. Heaney, Reg. No. 32,542  
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5311  
Facsimile: 703-243-6410  
Attorney Docket No.:MERCK-2952

Date: November 3, 2006